{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:20:34Z","timestamp":1774884034397,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.hlc.2024.05.002","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T10:56:48Z","timestamp":1717066608000},"page":"547-552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cardio-Oncology\u2014Beyond Anthracyclines and Ejection Fraction"],"prefix":"10.1016","volume":"33","author":[{"given":"Paul D.","family":"Geenty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann T.","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Robert","family":"Denniss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron L.","family":"Sverdlov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liza","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10159","key":"10.1016\/j.hlc.2024.05.002_bib1","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.hlc.2024.05.002_bib2","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2901","article-title":"Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study","volume":"13","author":"Patnaik","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"8","key":"10.1016\/j.hlc.2024.05.002_bib3","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jcmg.2018.06.005","article-title":"Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients","volume":"11","author":"Henry","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.hlc.2024.05.002_bib4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jaccao.2020.05.010","article-title":"Suboptimal use of cardioprotective medications in patients with a history of cancer","volume":"2","author":"Untaru","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"5","key":"10.1016\/j.hlc.2024.05.002_bib5","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.hlc.2023.04.301","article-title":"When cancer and cardiovascular gisease intersect: the challenge and\u00a0the\u00a0opportunity of cardio-oncology","volume":"33","author":"Sverdlov","year":"2024","journal-title":"Heart Lung Circ"},{"issue":"5","key":"10.1016\/j.hlc.2024.05.002_bib6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.hlc.2024.01.011","article-title":"Integrating cardio-oncology across the research pipeline; policy and practice in Australia\u2014an Australian Cardiovascular Alliance perspective","volume":"33","author":"Singleton","year":"2024","journal-title":"Heart Lung Circ"},{"issue":"5","key":"10.1016\/j.hlc.2024.05.002_bib7","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.hlc.2024.03.008","article-title":"Guideline-directed medical therapy in patients with heart failure with reduced ejection fraction and incident cancer","volume":"33","author":"Tini","year":"2023","journal-title":"Heart Lung Circ"},{"issue":"5","key":"10.1016\/j.hlc.2024.05.002_bib8","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.hlc.2024.03.003","article-title":"Higher mortality in patients with diffuse large B-cell lymphoma pre-existing arterial hypertension\u2014Real world data\u00a0of\u00a0the Polish Lymphoma Research Group","volume":"33","author":"Szmit","year":"2024","journal-title":"Heart Lung Circ"},{"issue":"5","key":"10.1016\/j.hlc.2024.05.002_bib9","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.hlc.2023.12.015","article-title":"High incidence of cardiovascular disease in patients with oesophageal cancer\u2014A registry-based cohort study","volume":"33","author":"S\u00f8ndergaard","year":"2024","journal-title":"Heart Lung Circ"},{"issue":"5","key":"10.1016\/j.hlc.2024.05.002_bib10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.hlc.2023.11.006","article-title":"Chest computed tomography for lymphoma staging: A wasted opportunity for cardiovascular risk stratification?","volume":"33","author":"Silva","year":"2024","journal-title":"Heart Lung Circ"},{"issue":"5","key":"10.1016\/j.hlc.2024.05.002_bib11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.hlc.2023.12.006","article-title":"Mechanisms of cardiovascular toxicities induced by cancer therapies and promising biomarkers for their prediction: A scoping review","volume":"33","author":"Yan","year":"2024","journal-title":"Heart Lung Circ"},{"issue":"5","key":"10.1016\/j.hlc.2024.05.002_bib12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.hlc.2023.10.004","article-title":"Rationale and design of the Cessation Of Pharmacotherapy in Recovered Chemotherapy-induced cardioToxicity (COP-RCT): A Pilot Study","volume":"33","author":"Yu","year":"2023","journal-title":"Heart Lung Circ"},{"issue":"5","key":"10.1016\/j.hlc.2024.05.002_bib13","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.hlc.2023.11.003","article-title":"Disparities in cardiovascular disease-related outcomes among cancer survivors in the United States: A systematic review of the literature","volume":"33","author":"Bikomeye","year":"2024","journal-title":"Heart Lung Circ"},{"issue":"22","key":"10.1016\/j.hlc.2024.05.002_bib14","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","article-title":"Cardio-Oncology Services: rationale, organization, and implementation","volume":"40","author":"Lancellotti","year":"2019","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.hlc.2024.05.002_bib15","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.hlc.2024.05.002_bib16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.hlc.2023.05.021","article-title":"Cardiovascular disease in patients with breast cancer treated in the modern era","volume":"33","author":"Murphy","year":"2024","journal-title":"Heart Lung Circ"},{"issue":"41","key":"10.1016\/j.hlc.2024.05.002_bib17","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.hlc.2024.05.002_bib18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11936-016-0465-7","article-title":"Exercise and aerobic fitness to reduce cancer-related cardiovascular toxicity","volume":"18","author":"Campia","year":"2016","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"32","key":"10.1016\/j.hlc.2024.05.002_bib19","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1200\/JCO.2014.56.7511","article-title":"Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin Lymphoma: A Report From the Childhood Cancer Survivor Study","volume":"32","author":"Jones","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hlc.2024.05.002_bib20","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jamaoncol.2018.2254","article-title":"Association of exercise with mortality in adult survivors of childhood cancer","volume":"4","author":"Scott","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.hlc.2024.05.002_bib21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.hlc.2024.05.002_bib22","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","article-title":"Cardio-Oncology: An update on cardiotoxicity of cancer-related treatment","volume":"118","author":"Lenneman","year":"2016","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.hlc.2024.05.002_bib23","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.hlc.2024.01.013","article-title":"Cancer therapies and cardiomyocyte viability: Which drugs are directly cardiotoxic?","volume":"33","author":"Balachandran","year":"2024","journal-title":"Heart Lung Circ"},{"issue":"8","key":"10.1016\/j.hlc.2024.05.002_bib24","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jcmg.2018.06.003","article-title":"Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient","volume":"11","author":"Plana","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"12","key":"10.1016\/j.hlc.2024.05.002_bib25","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/ejhf.1985","article-title":"The cancer patient and cardiology","volume":"22","author":"Zamorano","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.hlc.2024.05.002_bib26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacological therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hlc.2024.05.002_bib27","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ehjci\/jet159","article-title":"Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection","volume":"15","author":"Negishi","year":"2013","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"5","key":"10.1016\/j.hlc.2024.05.002_bib28","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.hlc.2023.06.864","article-title":"Alterations in left atrial strain in breast cancer patients immediately post anthracycline exposure","volume":"33","author":"Emerson","year":"2023","journal-title":"Heart Lung Circ"},{"issue":"5","key":"10.1016\/j.hlc.2024.05.002_bib29","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.hlc.2024.03.010","article-title":"Comparison of echocardiography and multi-planar gated acquisition scans for predicting cancer-treatment-related cardiovascular dysfunction","volume":"33","author":"Nolan","year":"2024","journal-title":"Heart Lung Circ"},{"issue":"5","key":"10.1016\/j.hlc.2024.05.002_bib30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.hlc.2024.02.007","article-title":"Cardiotoxicity in oncology guidelines: discrepancies do matter","volume":"33","author":"Tan","year":"2024","journal-title":"Heart Lung Circ"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S144395062400595X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S144395062400595X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T06:21:01Z","timestamp":1717654861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S144395062400595X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S144395062400595X"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2024.05.002","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardio-Oncology\u2014Beyond Anthracyclines and Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2024.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).","name":"copyright","label":"Copyright"}]}}